Trident Lifeline Ltd
Incorporated in 2014, Trident Lifeline Ltd manufactures and sells pharmaceuticals
products[1]
- Market Cap ₹ 306 Cr.
- Current Price ₹ 266
- High / Low ₹ 339 / 136
- Stock P/E 42.2
- Book Value ₹ 50.1
- Dividend Yield 0.00 %
- ROCE 14.7 %
- ROE 12.0 %
- Face Value ₹ 10.0
Pros
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company might be capitalizing the interest cost
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
|---|---|---|---|---|
| 21.77 | 31.69 | 44.63 | 55.30 | |
| 19.05 | 25.42 | 36.40 | 43.86 | |
| Operating Profit | 2.72 | 6.27 | 8.23 | 11.44 |
| OPM % | 12.49% | 19.79% | 18.44% | 20.69% |
| 0.60 | 1.16 | 2.08 | 2.41 | |
| Interest | 0.13 | 0.48 | 0.65 | 1.39 |
| Depreciation | 0.20 | 0.36 | 0.97 | 1.38 |
| Profit before tax | 2.99 | 6.59 | 8.69 | 11.08 |
| Tax % | -32.11% | 8.50% | 31.65% | |
| 3.95 | 6.02 | 5.94 | 7.24 | |
| EPS in Rs | 4.94 | 5.24 | 5.51 | 7.15 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 52% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 2% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 12% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
|---|---|---|---|---|
| Equity Capital | 8.00 | 11.50 | 11.50 | 11.50 |
| Reserves | -3.22 | 34.14 | 41.40 | 46.06 |
| 2.46 | 7.69 | 18.41 | 22.84 | |
| 6.60 | 9.25 | 15.77 | 17.46 | |
| Total Liabilities | 13.84 | 62.58 | 87.08 | 97.86 |
| 1.43 | 3.16 | 20.90 | 26.02 | |
| CWIP | 0.00 | 4.83 | 4.03 | 1.16 |
| Investments | 0.00 | 3.34 | 3.77 | 4.13 |
| 12.41 | 51.25 | 58.38 | 66.55 | |
| Total Assets | 13.84 | 62.58 | 87.08 | 97.86 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| -0.21 | -19.00 | 2.23 | |
| -0.45 | -9.69 | -20.36 | |
| 0.80 | 42.28 | 11.01 | |
| Net Cash Flow | 0.14 | 13.60 | -7.13 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | |
|---|---|---|---|
| Debtor Days | 83.33 | 139.25 | 109.92 |
| Inventory Days | 95.16 | 129.36 | 156.45 |
| Days Payable | 134.15 | 86.78 | 93.64 |
| Cash Conversion Cycle | 44.34 | 181.83 | 172.72 |
| Working Capital Days | 66.56 | 319.39 | 250.83 |
| ROCE % | 22.79% | 14.66% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
4 Jan - Certificate under Regulation 74(5) of SEBI regulations.
-
Intimation Of Change Of Name Of Registrar And Share Transfer Agent Of The Company.
2 Jan - Change of name of RTA to MUFG Intime.
- Closure of Trading Window 30 Dec
-
Announcement under Regulation 30 (LODR)-Acquisition
24 Dec - Acquisition of 51% stake in Trident Mediquip Limited.
-
Board Meeting Outcome for Outcome Of Board Meeting Held On December 23, 2024
23 Dec - Acquisition of 51% stake in Trident Mediquip Limited.
Business Overview:[1]
TFL is a pharmaceutical Company with business operations spanning formulations under its own brands, loan licence model and contract manufacturing model.
a) Pharmaceutical formulations export:
Company has a presence in 40 countries, including African, Latin America, and East
Asian countries, with ~945 registered export market products, and ~2016 export market products are under registration
b) Contract manufacturing:
Company follows an Asset-light third-party contract manufacturing model thus entailing limited direct investment in manufacturing capacities